This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 2:8:41.
doi: 10.3389/fphar.2017.00041. eCollection 2017.

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations

Affiliations

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations

Isabella P Godói et al. Front Pharmacol. .

Abstract

Introduction and Objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers' willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research. Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine. Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers' willingness to pay for CYD-TDV vaccine is US33ドル.61 (120.00BRL) for the complete schedule and US11ドル.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia® for three doses, only 17% of the population expressed willingness to pay for this vaccine. Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.

Keywords: Brazil; consumers; dengue; vaccine; willingness to pay.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Family income of respondents included in analysis of the willingness to pay for dengue vaccine (CYD-TDV) in this study. ∗NA, not available – The respondents that answered, "I do not know and I do not want to answer"; mw, minimal wage.
FIGURE 2
FIGURE 2
Cumulative percentage of individuals willing to pay for CYD-TDV vaccine according to the maximum values reported.
FIGURE 3
FIGURE 3
Box plot of the willingness to pay for three doses of CYD-TDV according to family income. NB. The results were statistically significant (<0.05); (∗) Extreme values presented for each income range; mw, minimal wage.

References

    1. Agência Brasil (2016). IBGE: Renda per Capita Média do Brasileiro Atinge R$ 1.113 em 2015. Available at: http://agenciabrasil.ebc.com.br/economia/noticia/2016-02/ibge-renda-capi...
    1. Agência Nacional de Saúde Suplementar [ANS] (2016a). Cadernos de Informações da Saúde Suplementar – Beneficiários, Operadoras e Planos. Available at http://www.ans.gov.br/images/stories/Materiais_para_pesquisa/Perfil_seto...
    1. Agência Nacional de Saúde Suplementar [ANS] (2016b). Dados Gerais - Beneficiários de Planos Privados de Saúde, por Cobertura assistencial (Brasil - 2006-2016). Available at: http://www.ans.gov.br/perfil-do-setor/dados-gerais
    1. Agência Nacional de Vigilância Sanitária [ANVISA] (2016). Preços Máximos De Medicamentos por Princípio Ativo. Available at: http://portal.anvisa.gov.br/documents/374947/2829072/LISTA+CONFORMIDADE_...
    1. Araújo D. V., Bahia L., Rendeiro M., Pinho A. S., Genovez V., Gonçalves T. M., et al. (2016). Estimation of the potential impact of dengue vaccination on clinical outcomes in Brazil. JBES 8 1–13.

LinkOut - more resources

Full text links
Frontiers Media SA full text link Frontiers Media SA Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /